EyeGene Inc Total Assets
EyeGene Inc total assets. Based on the latest financial reports, EyeGene Inc (185490) holds total assets worth ₩64.70 Billion KRW (≈ $43.85 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is EyeGene Inc worth for the company's overall valuation and market capitalisation.
Total Assets of EyeGene Inc (2014–2025)
Total assets of EyeGene Inc from 2014 to 2025. This chart illustrates how EyeGene Inc's total assets have evolved over time, based on quarterly financial data. See EyeGene Inc stock price for real-time trading data and today's change.
EyeGene Inc - Asset Composition Analysis
EyeGene Inc Total Assets Breakdown (December 2025)
EyeGene Inc total assets breakdown as of December 2025. EyeGene Inc's total assets of ₩64.70 Billion consist of 70.0% current assets and 30.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 15.0% |
| Accounts Receivable | ₩772.12 Million | 1.1% |
| Inventory | ₩750.72 Million | 1.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.90 Billion | 4.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how EyeGene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is EyeGene Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EyeGene Inc's current assets represent 70.0% of total assets in 2025, a decrease from 84.8% in 2014.
- Cash Position: Cash and equivalents constituted 15.0% of total assets in 2025, down from 46.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 5.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 4.3% of total assets.
EyeGene Inc Competitors by Total Assets
Key competitors of EyeGene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
EyeGene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.37 | 2.97 | 20.07 |
| Quick Ratio | 4.30 | 2.92 | 19.91 |
| Cash Ratio | 0.00 | 0.00 | 0.26 |
| Working Capital | ₩33.94 Billion | ₩22.75 Billion | ₩111.12 Billion |
EyeGene Inc - Advanced Valuation Insights
This section examines the relationship between EyeGene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | ₩68.05 Billion |
| Market Capitalization | $49.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values EyeGene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: EyeGene Inc's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for EyeGene Inc (2014–2025)
The table below shows the annual total assets of EyeGene Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩68.05 Billion ≈ $46.12 Million |
+4.20% |
| 2024-12-31 | ₩65.31 Billion ≈ $44.26 Million |
-16.38% |
| 2023-12-31 | ₩78.10 Billion ≈ $52.93 Million |
-2.83% |
| 2022-12-31 | ₩80.38 Billion ≈ $54.47 Million |
-23.44% |
| 2021-12-31 | ₩104.99 Billion ≈ $71.15 Million |
+136.32% |
| 2020-12-31 | ₩44.43 Billion ≈ $30.11 Million |
-6.09% |
| 2019-12-31 | ₩47.31 Billion ≈ $32.06 Million |
-12.46% |
| 2018-12-31 | ₩54.04 Billion ≈ $36.62 Million |
+78.46% |
| 2017-12-31 | ₩30.28 Billion ≈ $20.52 Million |
+63.20% |
| 2016-12-31 | ₩18.56 Billion ≈ $12.58 Million |
-23.72% |
| 2015-12-31 | ₩24.33 Billion ≈ $16.49 Million |
+338.90% |
| 2014-12-31 | ₩5.54 Billion ≈ $3.76 Million |
-- |
About EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more